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Introduction: When influenza vaccination is ineffec-
tive in preventing influenza virus infection, it may still 
reduce the severity of influenza-associated disease. 
Here, we estimate the effect of influenza vaccination 
in preventing severe outcomes e.g. intensive care 
unit (ICU) admission and death, even though it did 
not prevent influenza virus infection and subsequent 
hospitalisation. Methods: An observational case–case 
epidemiological study was carried out in 12 sentinel 
hospitals in Catalonia (Spain) over six influenza sea-
sons 2010/11–2015/16. Cases were individuals with 
severe laboratory-confirmed influenza virus infection 
and aged 18 years and older. For each reported case 
we collected demographic, virological and clinical 
characteristics. Logistic regression was used to esti-
mate the crude, adjusted odd ratios (aOR) and 95% 
confidence intervals (CI). Results: Of 1,727 hospital-
ised patients included in the study, 799 were female 
(46.7%), 591 (34.2%) were admitted to the ICU and 223 
(12.9%) died. Influenza vaccination uptake was lower 
in cases that required ICU admission or died (21.2% vs 
29.7%, p  < 0.001). The adjusted influenza vaccination 
effectiveness in preventing ICU admission or death 
was 23% (95% CI: 1 to 40). In an analysis restricted to 
sex, age group and antiviral treatment, influenza vac-
cination had a positive effect on disease severity in 
all age groups and categories. Conclusions: We found 
that influenza vaccination reduced the severity of dis-
ease even in cases where it did not prevent infection 
and influenza-associated hospitalisation. Therefore, 
increased vaccination uptake may reduce complica-
tions, ICU admission and death.
Introduction
Each year, 5–20% of the global population are infected 
by the influenza virus, which is estimated to result in 
3–5 million cases of severe illness and 300,000 to 
500,000 deaths worldwide [1].
Influenza surveillance is essential to determine the 
timing and spread of influenza and trace variations in 
circulating influenza viruses to provide information on 
the composition of the seasonal influenza vaccine [2]. 
Sentinel surveillance of patients hospitalised due to 
severe laboratory-confirmed influenza has shown that 
influenza is an important cause of severe illness and 
death, mainly among those aged  65 years and older 
and patients with underlying chronic diseases [3].
The influenza vaccine is the best tool for the preven-
tion of influenza and its complications, particularly in 
patients with underlying chronic diseases and those 
aged 65 years and older [4-7]. Influenza vaccination is 
effective in preventing primary healthcare visits and 
hospital admissions for laboratory-confirmed influ-
enza [8], but chronic conditions and other risk factors, 
including older ages, may interfere with and hinder a 
successful vaccine response [9,10].
When influenza vaccination is ineffective in preventing 
influenza virus infection it may still have an additional 
effect by reducing the severity of influenza [11]. It has 
been suggested that while protection against influenza 
virus infection is primarily mediated through the anti-
body response, protection against severe outcomes is 
mediated through cellular immune responses affecting 
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viral clearance [4,11]; however, the effect of influenza 
vaccination on influenza severity remains uncertain. 
While some studies evaluating hospital admission in 
patients with laboratory-confirmed influenza have 
failed to demonstrate a protective effect of influenza 
vaccination [12,13], others have found it has an effect 
on reducing influenza severity [14]. Case–case stud-
ies are considered the best approach to estimate a net 
effect of influenza vaccination on the post-infection 
outcomes only in subjects who become infected [15].
In 2010, Catalonia, a region in the north-east of Spain 
with 7.5 million inhabitants, initiated surveillance of 
patients hospitalised due to laboratory-confirmed 
influenza with the aim of (i) estimating the severity of 
seasonal influenza epidemics according to the char-
acteristics of the influenza virus, (ii) identifying risk 
groups for severity and, (iii) providing information to 
improve influenza prevention and control. The system 
includes 12 hospitals covering 4,644,543 persons (62% 
of the entire population) [16]. The surveillance system 
reports on patients hospitalised with severe labora-
tory-confirmed influenza admitted to one of these 
hospitals every influenza season since 2010/11. The 
hospital-based surveillance was set up to supplement 
the information provided by the influenza sentinel sur-
veillance system based on surveillance information 
from primary healthcare network physicians [16].
The presented study aimed to estimate the effect 
of influenza vaccination during influenza seasons 
2010/11–2015/16 in preventing severe outcomes, e.g. 
intensive care unit (ICU) admission and death, when 
the influenza vaccination did not prevent influenza and 
subsequent hospitalisation.
Methods
We conducted a hospital-based observational case–
case epidemiological study on the effect of influenza 
vaccination in reducing disease severity in patients 
hospitalised due to laboratory-confirmed influenza 
over six influenza seasons (2010/11–2015/16).
Study population and data collected
The study population were all reported cases that were 
those 18 years and older that had been hospitalised 
with severe laboratory-confirmed influenza virus infec-
tion in the 12 sentinel hospitals in Catalonia during six 
influenza seasons (2010/11–2015/16).
We included patients that had been hospitalised for 
more than 24 hours in any of the 12 participating hos-
pitals due to influenza-like-illness (ILI) with symptom 
onset more than 7 days before admittance. Definition 
for ILI based on the European Union case definition [17] 
can be seen in Box.
Patients were recruited in one of the participating hos-
pitals by a sentinel physician who screened all patients 
admitted overnight presenting with severe ILI. All 
patients had a nasopharyngeal or throat swab (bron-
choalveolar lavage fluid or tracheal aspirate for ICU 
patients) and influenza virus infection was detected 
using reverse transcription polymerase chain reaction 
(RT-PCR).
Public health officers from the surveillance units in 
Catalonia, collected data from each reported case by 
interview using a structured questionnaire from the 
epidemiological surveillance network. Information 
included socio-demographic data, obesity (body mass 
index (BMI) > 40), pregnancy, major chronic conditions 
(e.g. asthma, chronic obstructive pulmonary disease 
(COPD), chronic renal disease, immunodeficiency (HIV 
infection or other), chronic cardiovascular disease, 
chronic liver disease).
In addition, information on the laboratory diagnosis, 
symptom onset, hospital admission and discharge 
dates, complications (primary or secondary pneumo-
nia with or without bacterial coinfection, respiratory 
distress syndrome or multiple organ failure), antiviral 
treatment, influenza vaccination status and date of 
administration, ICU admission, and death were col-
lected from medical records for all reported cases.
Laboratory data
Patient samples were first tested for type of virus in 
the laboratories of the participating hospitals using an 
in-house real-time influenza A and B PCR after manual 
nucleic acid extraction. Amplification was performed 
in an ABI 7500 thermocycler. All samples, including 
those with unsubtyped influenza virus, were sent to 
the Catalan Influenza Reference Centre (Hospital Clinic, 
Barcelona, Spain) to determine the subtype. Samples 
found to be positive in the reference centre were molec-
ularly subtyped for viruses known to be circulating at 
Box 
Influenza-like-illness case definition, Catalonia, Spain, 
influenza seasons 2010/11—2015/16 
Influenza-like-illness (ILI) was defined as a combination of 
the following three criteria:
(i) Sudden symptom onset:
(ii) ≥ 1 of the following symptoms:
• fever (≥ 38 °C)
• headache
• myalgia or malaise
and
(iii) ≥ 1 of the following respiratory symptoms:
• cough
• sore throat or
• shortness of breath (dyspnea).
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the time, namely type A (subtypes H1N1pdm09 and 
H3N2) and type B. Molecular subtyping was used to 
determine the H subtype for influenza A and the lin-
eage for influenza B. Subtyping failed in some cases 
due to a low viral load and such samples were classi-
fied as ‘unidentifiable’. 
Statistical analysis
We compared hospitalised cases of severe influenza 
who required ICU admission or those who died at the 
hospital after being admitted, with hospitalised cases 
of severe influenza that did not require ICU admission 
and did not die. We compared baseline characteristics 
and vaccination status between the two groups. The 
baseline variables considered were: sex, age (18–64 
years, and those aged 65 years and older), virus (sub)
types, major chronic conditions, pregnancy, complica-
tions and antiviral treatment. The chi-squared test and 
Fisher’s exact test were used for categorical variables 
and the t-test for continuous variables for comparisons 
between the groups.
To investigate relationships between the dependent 
variables (ICU admission or death) and the independent 
variables studied (including influenza vaccination), a 
case–case bivariate analysis was conducted. Possible 
interactions between influenza vaccination status and 
any independent variable were analysed by logistic 
regression. Independent variables were checked for 
collinearity using the variance inflation factor (Katz).
The effectiveness of influenza vaccination was cal-
culated using the formula vaccine effectiveness 
(VE)  =  (1  −  odds ratio)  x  100. Logistic regression was 
used to estimate the crude and adjusted odds ratios 
(aOR) and their corresponding 95% confidence inter-
vals (CI). A multivariate analysis was performed using 
the change-in-estimate criterion, including poten-
tial confounders in the model when the OR changed 
by ≥  10%. Since influenza vaccination rates among 
those aged 65 years and older were high and increased 
substantially with age, to account for dissimilar distri-
butions of baseline characteristics between vaccinated 
and unvaccinated groups and to reduce confounding, 
Table 1
Characteristics of patients hospitalised due to laboratory-confirmed influenza, Catalonia, influenza seasons 2010/11–2015/16 
(n = 1,711)
Characteristics
Total Vaccinated Unvaccinated
p value
n % n % n %
All cases 1,711 100 450 100 1,261 100 NA
Sex
Male 975 57 264 58.7 711 56.4
0.401
Female 736 43 186 41.3 550 43.6
Age
18–64 799 46.7 71 15.8 728 57.7
< 0.001
≥ 65 912 53.3 379 84.2 533 42.3
Type of influenza virus
A 1,470 85.9 375 83.3 1,095 86.8
0.067
B 241 14.1 75 16.7 166 13.2
Comorbidities
Obesity (BMI > 40) 181 10.6 50 11.1 131 10.4 0.669
COPD 441 25.8 159 35.3 282 22.4 < 0.001
Diabetes mellitus 425 24.8 156 34.6 269 21.3 < 0.001
Chronic renal disease 235 13.7 94 28.9 141 11.2 < 0.001
Immunodeficiency 333 19.5 74 16.4 259 20.5 0.060
Chronic cardiovascular disease 504 29.5 202 44.9 302 23.9 < 0.001
Chronic liver disease 112 6.5 21 4.7 91 7.2 0.063
Complications
Pneumonia 1,277 74.9 316 70.2 961 76.2 0.016
ARD 1,019 60.8 144 32.0 513 40.7 0.001
Multi-organ failure 176 10.6 40 8.9 136 10.8 0.270
ICU admission 591 34.5 108 24.0 483 38.3 < 0.001
Death 223 13.0 63 14.0 160 12.7 1.533
Pregnancya 26 1.5 0 0.0 26 2.1 NC
ARD: Acute respiratory distress; BMI: body mass index; COPD: chronic obstructive pulmonary disease; ICU: intensive care unit; NA: not 
applicable; NC: not calculable.
aPregnancy was not considered a complication and was in another category.
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Table 2
Factors associated with intensive care unit admission and death, Catalonia, influenza seasons 2010/11–2015/16 (n = 1,727)
Characteristics
ICU/death 
 
(n = 692)
Non-ICU/death (n = 1,035)
Crude OR 95% CI
p value
n % n %
Seasonal vaccination
Yes 146 21.3 304 29.7 0.64 (0.51 to 0.80) < 0.001
No 540 78.7 721 70.3 Ref
Age
18–64 years 386 55.8 422 40.8 Ref
≥ 65 years 306 44.2 613 59.2 0.55 (0.45 to 0.66) < 0.001
Sex
Male 271 39.2 472 45.6 0.77 (0.63 to 0.93) 0.008
Female 421 60.8 563 54.4 Ref
Type of virus
A 602 87 883 85.3 1.15 (0.87 to 1.52) 0.325
B 90 13 152 14.7 Ref
COPD
Yes 187 27.0 255 24.6 1.13 (0.91 to 1.41) 0.27
No 505 73.0 780 75.4 Ref
Obesity
Yes 87 12.6 95 9.2 1.42 (1.04 to 1.94) 0.02
No 605 87.4 940 90.8 Ref
Diabetes mellitus
Yes 170 24.6 261 25.2 0.97 (0.77 to 1.21) 0.76
No 522 75.4 774 74.8 Ref
Chronic renal disease
Yes 100 14.5 136 13.1 1.12 (0.84 to 1.47) 0.44
No 592 85.5 899 86.9 Ref
Immunodeficiency
Yes 159 23.0 177 17.1 1.45 (1.14 to 1.84) 0.003
No 533 77.0 858 82.9 Ref
Chronic cardiovascular disease
Yes 196 28.3 312 30.1 0.92 (0.74 to 1.13) 0.42
No 496 71.7 723 69.9 Ref
Chronic liver disease
Yes 58 8.4 55 5.3 1.63 (1.11 to 2.39) 0.01
No 634 91.6 980 94.7 Ref
Pregnancy
Yes 16 2.3 10 1.0 2.43 (1.09 to 5.38) 0.03
No 676 97.7 1025 99.0 Ref
NI treatment
Yes 635 91.8 942 91.0 1.10 (0.78 to 1.55) 0.59
≤ 48h symptom onset 154 23.1 283 28.4 0.89 (0.60 to 1.30) 0.54
> 48h symptom onset 455 68.3 619 62.2 1.20 (0.84 to 1.70) 0.31
No 57 8.6 93 9.3 Ref
Number of risk factors
0 172 24.9 270 26.1 0.78 (0.58 to 1.06) 0.11
1 241 34.8 378 36.5 0.78 (0.59 to 1.04) 0.09
2 155 22.4 235 22.7 0.81 (0.62 to 1.10) 0.18
> 2 124 17.9 152 14.7 Ref
Hospital stay
0–7 days 145 21 539 52.1 0.24 (0.197 to 0.30) < 0.001
> 7 days 545 79 145 21 Ref
Hospital stay
0–14 days 335 48.6 859 83 0.19 (0.15 to 2.41) < 0.001
> 14 days 355 51.4 176 17 Ref
CI: confidence interval; COPD: chronic obstructive pulmonary disease; ICU: intensive care unit; NI: Neuraminidase inhibitors; OR: odds ratio; 
Ref: reference.
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we predicted the probability of influenza vaccination 
using the propensity score method. The propensity 
score was estimated by logistic regression with sea-
sonal influenza vaccination as the outcome and age, 
sex, comorbidities, pregnancy, type of virus and anti-
viral treatment as independent variables. The propen-
sity score was used as a continuous covariate in a final 
logistic regression model.
To assess the robustness of the estimate, influenza VE 
was also calculated in patient subgroups according to 
sex, age and antiviral treatment. The analysis was per-
formed using the SPSS v.24 statistical package and the 
R v3.3.0 statistical software [18].
Results
A total of 1,727 patients aged 18 years and older hos-
pitalised with severe laboratory-confirmed influenza 
were Included in the study, of which 736 (43.0%) were 
female, 799 (46.7%) were aged 18–64 years and 912 
(53.3%) were aged 65 years or older. In the six seasons 
studied (2010/11–2015/16), 1,470 (85.9%) patients 
were infected with influenza A viruses (H1N1 = 572 and 
H3N2  =  572) and 241 (14.1%) with influenza B viruses. 
Of the 1,727 patients, 591 (34.2%) were admitted to 
the ICU and 223 (12.9%) died. A total of 1,285 (74.4%) 
patients presented with one or more influenza risk fac-
tors, but only 450 (26.1%) had received the influenza 
vaccine. Influenza vaccination uptake was similar in 
males and females (27.1% vs 25.3%) but higher in 
those aged 65 years or older compared with those aged 
18–64 years (41.6% vs 8.9%). There were 26 pregnant 
women, none of which were vaccinated (Table 1).
There were differences between patients admitted to 
the ICU or who died and those who did not. Patients 
who required ICU admission or died were more fre-
quently male (60.8% vs 54.4%, p < 0.001), aged 18–64 
years (55.8% vs 40.8%, p  <  0.001), obese (12.6% vs 
9.2%, p  =  0.02), immunodeficient (23.0% vs 17.1% 
p < 0.001), had chronic liver disease (8.4% vs 5.5% 
p = 0.01), were pregnant (2.3% vs 1% p = 0.03) and a 
higher proportion stayed in hospital more than 14 days 
(51.4% vs 17.0%, p  < 0.001), but there were no differ-
ences in vaccinated patients vs unvaccinated patients 
in the average length of hospital stay (14.11 ± 15.58 and 
15.01 ± 16.16 days, respectively; p = 0.31), the type of 
virus or whether antiviral treatment was administered 
before or after 48 hours after hospital admission (Table 
2).
Influenza vaccination uptake was lower in patients 
who required ICU admission or died (146/686: 21.3% vs 
304/1025: 29.7%, p  < 0.001) (Table 2). The unadjusted 
influenza VE in preventing ICU admission or death was 
36% (95% CI: 20 to 49) and, except in one season 
(2013/14), had a positive effect in all influenza sea-
sons, although the effect was not significant in some 
seasons (2010/11, 2011/12, 2012/13 and 2013/14) (data 
not shown).
In the multivariable regression model, the variables 
associated with ICU admission or death were in those 
aged 65 years or older (aOR: 0.56; 95% CI: 0.45 to 0.68) 
and comorbidities (aOR: 1.36; 95% CI: 1.07 to 1.73). 
The adjusted effectiveness of influenza vaccination 
in preventing ICU admission or death was 22% (95% 
CI: 1 to 39) and remained the same after adjustment 
by the propensity score (23%; 95% CI: 1 to 40) (Table 
3, propensity score data not shown). In the analysis 
restricted to sex, age group and antiviral treatment, 
influenza vaccination had a positive effect in all groups 
and categories, although in females and those aged 65 
years and older, the effectiveness was lower and was 
not significant (Table 4).
Table 3
Effect of influenza vaccination in reducing severe outcomes in patients hospitalised due to laboratory-confirmed influenza, 
Catalonia, Spain, influenza seasons 2010/11–2015/16 (n = 1,727)
Characteristics
ICU/death 
 
(n = 692)
Non-ICU/death (n = 1,035)
Adjusted OR 95% CI p value
n % n %
Seasonal vaccine
Yes 146 21.3 304 29.7 0.78 (0.61 to 0.99) 0.048
No 540 78.7 721 70.3 Ref
Age
18-64 years 386 55.8 422 40.8 Ref
≥ 65 years 306 44.2 613 59.2 0.56 (0.45 to 0.68) < 0.001
Comorbidities
Yes 520 75.1 765 73.9 1.36 (1.07 to 1.73) 0.011
No 172 24.9 270 26.1 Ref
CI: confidence interval; ICU: intensive care unit; OR: odds ratio; Ref: reference.
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Discussion
This study, based on surveillance of hospitalised 
cases of severe laboratory-confirmed influenza from 
2010/11–2015/16 in Catalonia, showed an effective-
ness of influenza vaccination in reducing ICU admis-
sion or death of 23%. Most patients presented with 
more than one influenza risk factor, but only 26.1% had 
received seasonal influenza vaccination, suggesting an 
important potential impact of vaccination in reducing 
influenza severity.
Our results are consistent with other studies, for exam-
ple, a study conducted in the United States (US) by 
Catania et al. also found that patients requiring ICU 
admission had a lower influenza vaccination cover-
age [19]; A Spanish study by Casado et al. found that 
influenza vaccination was associated with a reduction 
in the odds of in-hospital death and ICU admission in 
adults hospitalised with laboratory-confirmed influ-
enza [20]and a French study by Loubet et al. reported a 
reduction in the risk of ICU admission but not death in 
patients hospitalised with laboratory-confirmed influ-
enza [21]. Our results and those of these studies, sug-
gest that influenza vaccination is a factor for a good 
prognosis, as it reduces influenza-associated disease 
severity in patients, in whom vaccination did not pre-
vent influenza.
A similar population-based study of patients hospi-
talised with laboratory-confirmed influenza by Arriola 
et al. conducted in the US during influenza season 
2012/13 [22] reported that 71% of patients were aged 
65 years or older, 91% had medical conditions and 
55% had been vaccinated. No association was found 
between influenza vaccination and ICU admission, 
death, pneumonia, or the length of hospital or ICU 
stay. However, after matching patients by the vacci-
nation propensity score, they found that the length of 
ICU stay was reduced by a factor of 0.6 (95%CI: 0.4 to 
0.8) among vaccinated 50–64 year olds compared with 
unvaccinated patients [22]. This is partly in line with 
our findings, as while we found a shorter length of hos-
pital stay in vaccinated patients than in unvaccinated 
patients the difference was not statistically significant.
Further, a study by Castilla et al. [23] also looking at 
hospitalised cases with laboratory-confirmed influ-
enza found that vaccination protected against severe 
influenza (aOR: 0.42; 95% CI: 0.22 to 0.80) and sug-
gested that vaccination might be more effective in pre-
venting severe than mild illness [23].
The influenza vaccination uptake in those aged 65 
years and older in this study (41.6%) was lower than 
that of the same age group in the Spanish general 
population (55.5%) [24], and suggests that improving 
influenza vaccination coverages may have a notewor-
thy effect in reducing influenza severity.
Two main approaches are currently used to estimate the 
post-infection effects of vaccination. The first includes 
all studied individuals whether they become infected 
or not, and relies on of the following study designs: 
cohort, case–control or test-negative case–control. 
This approach enjoys the statistical validity associated 
with an intent-to-treat analysis and provides an assess-
ment of the overall benefits of vaccination. However, 
such an approach does not distinguish between vac-
cine effects on susceptibility to infection and effects 
on the post infection endpoints of interest.
The second approach, which we used, includes only 
infected individuals and relies on a case–case study 
design. It uses the positive infection status to estimate 
the net effect of the vaccination on the post-infection 
endpoint. However, individuals that are infected, 
even though vaccinated, are unlikely to be identical 
to infected individuals that are unvaccinated and this 
Table 4
Effect of seasonal influenza vaccination in reducing severity among subgroups of patients hospitalised due to laboratory-
confirmed influenza, Catalonia, Spain, influenza seasons 2010/11–2015/16 (n = 1727)
Analysis subset ICU/death Non-ICU/death Crude vaccination effect 95% CI Adjusted vaccination effect (%) 95% CI p-value
Sex
Female 271 472 27 -5 to 49 3 -43 to 34 0.886
Male 421 563 43 22 to 57 33 8 to 51 0.014
Age
18–64 386 422 6 -53 to 43 13
-42 to 
47 0.574
≥ 65 306 613 33 -2 to 42 25 -1 to 43 0.050
NI treatment
Yes 635 942 36 18 to 49 21 -2 to 39 0.070
No 57 93 37 -30 to 70 57 2 to 81 0.031
CI: confidence interval; ICU: intensive care unit; NI: Neuraminidase inhibitors.
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can lead to biased interpretations. For example, a vac-
cine might better protect people with strong immune 
systems, so that infected vaccines tend to have weaker 
immune systems on average compared with infected 
unvaccinated cases. As a result, infected vaccinated 
persons could have worse post-infection outcomes on 
average than the infected controls due solely to selec-
tion bias and the estimate of VE in reducing severity 
could be underestimated [15].
As our study is based on a case–case analysis of 
patients hospitalized with severe laboratory-confirmed 
influenza, the vaccination effect should be attributed 
to the capacity to reduce severity after influenza infec-
tion had occurred. We do not know through which 
mechanisms vaccination prevents severity. While pro-
tection against influenza infection is primarily medi-
ated by inducing antibodies, protection against severe 
influenza-related outcomes is mediated through the 
cellular immune responses affecting viral clearance 
[25,26]. Unlike antibodies, induced by rapidly mutating 
surface proteins, cell-mediated immunity to influenza 
is primarily induced by the major internal virus proteins 
that are generally more conserved across subtypes, 
allowing for greater heterologous cross-reactivity [27]. 
It is suggested that individuals previously infected by 
seasonal human influenza A viruses or who received 
seasonal human influenza vaccines may derive ben-
efits, at least in part, from the pre-existing cross-reac-
tive memory of cytotoxic T lymphocytes in reducing the 
severity of A(H1N1)pdm infection, even without protec-
tive antibodies [25].
There were some mismatching seasons (2014/15 for 
influenza A virus and seasons 2011/12, 2013/14 and 
2015/16 for influenza B virus) that may have had some 
influence on influenza VE.
Strengths and limitations
The strengths of the study include the large number 
of patients hospitalised for influenza, the multicentre 
design, uniform patient screening by hospitals, diag-
nostic confirmation of all patients and the extended 
study period of six consecutive influenza seasons 
(2010/11–2015/16).
The study also had some limitations. First, individu-
als aged 65 years and older may be less likely to be 
admitted to the ICU [28], which may have reduced 
the number of outcomes and the statistical power of 
the study. Second, although we included a number of 
potential confounders in the multivariate model, there 
might be unmeasured confounders associated with 
vaccination and severe influenza [29]. Third, as the 
likelihood of ICU admission was greater in those aged 
64 and younger and the risk of death was greater in 
those aged 65 years and older, grouping of patients by 
these outcomes and age may have underestimated VE. 
For this reason, we also estimated the influenza VE in 
those aged 65 years and older, which was higher (25%) 
than in people aged 18–64 years (13%). Other studies 
have applied this grouping of death and ICU admission 
as an outcome of influenza-associated disease severity 
[21,23]. Finally, physicians may have been more likely 
to test for influenza virus in patients presenting with 
more-severe ILI, underestimating the benefit of vacci-
nation. However, as physicians were not aware of the 
vaccination status of patients it is unlikely that influ-
enza vaccination produced a sampling bias. We only 
assessed in-hospital deaths we were unable to include 
deaths that occurred after discharge from hospital.
In conclusion, most patients hospitalised for severe 
influenza are aged 65 years and older and have under-
lying medical conditions, leading to a higher risk of 
influenza-associated complications, ICU admission 
and death. Influenza vaccination could reduce ICU 
admission and death in these patients, by reducing 
the severity of the disease. This effect complements 
the effectiveness of influenza vaccination in avoiding 
infection, especially in patients with underlying condi-
tions, in whom influenza vaccination is frequently not 
optimal in preventing infection. Almost all the patients 
in this study qualified for influenza vaccination accord-
ing to national guidelines [30]. Increased vaccination 
uptake might reduce the number of complications and 
ICU admissions. Annual influenza vaccination is still 
the best measure against influenza virus infection and 
its complications, particularly for populations at risk of 
more severe disease.
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